February 2010 - Volume 21 - Issue 2 - Contributor Index

Alphabetical Search
E
I
O
Q
U
X
Y
Author:
Abbara, Chadi

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Author:
Cao, Peter
Author:
Carli, Paolo

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Chung, Caroline
Author:
Cibert, Marion
Author:
Cree, Ian A.
Author:
Daw, Hamed A.
Author:
Donach, Martin

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Dunham, Thomas

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Farina, Miriam

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Furini, Lara

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Gioia, Magda
Author:
Gonin, Patrick
Author:
Hosten, Benoît
Author:
Huang, Hsu-Shan
Author:
Huang, Kuo-Feng
Author:
Koutantos, John

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Author:
Lee, Chia-Chung
Author:
Li, Cho-Lu
Author:
Lin, Jing-Jer

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Author:
Milzani, Aldo
Author:
Myc, Andrzej

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Author:
Petit, Benoît
Author:
Rossi, Ranieri
Author:
Smith, Jason

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Author:
Swanson, Ben

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study

Stathopoulos, George P.; Ardavanis, Alexandros; Papakotoulas, Pavlos; More

Anti-Cancer Drugs . 21(2):202-205, February 2010.

Author:
Weber, David J.

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.

Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma

Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; More

Anti-Cancer Drugs . 21(2):210-213, February 2010.